The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1476
Onexton Gel for Acne
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved another fixed combination of the antibiotic clindamycin phosphate and the oxidizing agent benzoyl peroxide (Onexton Gel 1.2%/3.75% – Valeant) for topical treatment of acne in patients ≥12 years old. Topical products containing the same drugs have been available for many years. Onexton Gel contains a new strength of benzoyl peroxide.

STANDARD TREATMENT — Benzoyl peroxide has antibacterial activity against Propionibacterium acnes. A pooled analysis of data from 12 randomized, vehicle-controlled trials found that topical benzoyl peroxide monotherapy reduced inflammatory and noninflammatory acne lesions by 52.1% and 41.5%, respectively, in patients with mostly mild to moderate acne.1 Topical clindamycin and erythromycin, which have both antibacterial and anti-inflammatory properties, are commonly used in addition to treat acne that has ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Onexton Gel for Acne
Article code: 1476d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian